Summary & Overview
HCPCS Level II J8700: Temozolomide, Oral, 5 mg
HCPCS Level II code J8700 denotes temozolomide, oral, 5 mg, an oral chemotherapy agent used in oncology care. Nationally, accurate coding for orally administered antineoplastics matters for appropriate pharmacy reimbursement, claims processing, and patient access to specialty medications. This analysis covers major national payers, including Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will find a concise overview of the code’s clinical context and service setting, payer coverage considerations, and commonly used claim modifiers. The publication outlines typical billing and service-line implications for outpatient pharmacy and clinic dispensing, and provides benchmarks and policy update highlights relevant to oral chemotherapy reimbursement. The report is designed to inform coding accuracy, administrative workflows, and payer communication for organizations managing oral oncology therapies.
Billing Code Overview
HCPCS Level II code J8700 represents temozolomide, oral, 5 mg. This code is used to report dispensing of the oral alkylating agent temozolomide in the 5 mg strength. The service type associated with this code is oral chemotherapy medication dispensing, and the typical site of service is outpatient pharmacy or outpatient clinic dispensing to patients for at-home administration.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult or pediatric oncology patient receiving oral temozolomide (J8700, temozolomide, oral, 5 mg) as part of chemotherapy for a primary or metastatic central nervous system malignancy (for example, glioblastoma multiforme) or for specific systemic malignancies where temozolomide is indicated. The clinical workflow begins with an oncologist consultation in an outpatient infusion or oncology clinic; the provider documents diagnosis, planned regimen and dosage calculations. The prescription for temozolomide is written and transmitted to either an on-site outpatient pharmacy or a specialty pharmacy. Prior to dispensing, pharmacy verifies the prescription, checks for drug interactions and organ-function appropriateness, and prepares the oral medication in the prescribed dosing schedule. Patient education is provided regarding dosing schedule (typically daily for a defined cycle), common adverse effects (nausea, myelosuppression), and monitoring requirements. Laboratory monitoring (complete blood count, metabolic panel) is ordered before treatment initiation and at scheduled intervals during therapy. If patient receives supportive services (antiemetics, growth factor support), those are documented separately. Billing uses the HCPCS code J8700 reported per unit (5 mg) with appropriate modifier(s) to indicate circumstances such as administrative direction, billing oversight, or reduced services. Typical sites of service include outpatient oncology clinics, physician office-based oncology practices, specialty pharmacies, and hospital outpatient departments.
Coding Specifications
| Modifier | Description | When to Use |
|---|